Inserm Transfert
Technology transfer office for Inserm biomedical researchers, handling patents, licences and industry partnerships in life sciences
Highlights
- New on EvolcAdded 2026-10-28
About Inserm Transfert
Inserm Transfert is the private subsidiary of Inserm, operating under a public service delegation, and specialises in transferring technologies from life sciences research and in finding collaborative funding for research projects. It protects research results through patents, supports research units in developing their projects, and matures early-stage technologies, including under the France 2030 maturation programme.
Its customers are Inserm researchers and research units, industrial partners and investors. The company also runs a pre-entrepreneurial pathway for researchers and the Human Health Startup Factory programme, and it has announced consortia for research-based collaboration including CATRIEM, COMBIO and COMS@N.
Founded in 2000, Inserm Transfert is headquartered in Paris and reported 104 employees in 2025. The company is recruiting business development managers, patent lawyers and patent engineers, and project managers for collaborative scientific and industrial projects.
Product: Technology transfer and valorisation services for Inserm research: patent protection, maturation funding, project development and industrial partnerships.
Jobs at Inserm Transfert
More biotech & pharma companies
Ipcure
Develops selective caspase-2 inhibitors and research tools for life sciences researchers and drug development teamsYoung companyNew on EvolcIpsomedic
Develops pharmaceutical active-ingredient manufacturing processes for domestic production in FranceNew on EvolcIris Pharma
Ophthalmology-focused preclinical and clinical research services for pharmaceutical and medical-device developersNew on EvolcJANVIER LABS
Supplies and manages experimental rodent models and related services for biomedical researchersNew on EvolcSalary transparentKcas Bio
Bioanalytical laboratory and CRO services for pharmaceutical and biotechnology sponsors developing drugsNew on EvolcKekkan Biologics
Develops antibody biologics for cancer and fibrotic disorders, initially targeting triple-negative breast cancerYoung companyNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Apache
- Bootstrap
- Cloudflare
- Matomo
- PHP
- WordPress
- jQuery
